ストックスクリーナーアプリを入手
16.11
5.09%
0.78
アフターアワーズ：
16.12
0.01
+0.06%
前日終値:
$15.33
開ける：
$16.35
24時間の取引高:
137.92K
Relative Volume:
1.84
時価総額：
$2.75B
収益：
$420.26M
当期純損益:
$-41.97M
株価収益率:
-64.44
EPS:
-0.25
ネットキャッシュフロー:
$-65.34M
1週間 パフォーマンス:
+16.74%
1か月 パフォーマンス:
+13.37%
6か月 パフォーマンス:
-10.15%
1年 パフォーマンス:
+11.26%
1日の値動き範囲:
$16.03
$16.50
1週間の範囲:
$13.58
$16.50
52週間の値動き範囲:
$12.84
$21.92
Hutchmed China Limited Adr Stock (HCM) Company Profile
HCM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HCM
Hutchmed China Limited Adr
|
16.11 | 2.75B | 420.26M | -41.97M | -65.34M | -0.25 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-11-24 | アップグレード | Deutsche Bank | Hold → Buy |
| 2022-05-04 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2021-09-22 | ダウングレード | Goldman | Buy → Neutral |
| 2021-08-03 | 開始されました | Jefferies | Buy |
| 2020-10-02 | 開始されました | Deutsche Bank | Buy |
| 2020-03-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-02-20 | 開始されました | Goldman | Buy |
| 2019-11-19 | 開始されました | CLSA | Buy |
| 2019-10-23 | 繰り返されました | BofA/Merrill | Buy |
| 2019-07-05 | 開始されました | Macquarie | Outperform |
すべてを表示
Hutchmed China Limited Adr (HCM) 最新ニュース
HUTCHMED (HCM) Upgraded to Buy: Here's Why - Yahoo Finance
Wall Street Analysts Believe HUTCHMED (HCM) Could Rally 72.83%: Here's is How to Trade - Yahoo Finance
ABC Arbitrage SA Buys New Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - MarketBeat
Crossmark Global Holdings Inc. Increases Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
CN Healthcare Fund Breaks even w/ Slim Surplus in 2024 - AASTOCKS.com
HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC - GlobeNewswire
UBS Trims HUTCHMED (00013.HK)TP to $38.7 w/ Rating Buy - AASTOCKS.com
Private equity firms are HUTCHMED (China) Limited's (LON:HCM) biggest owners and were rewarded after market cap rose by UK£120m last week - Yahoo Finance
HSBC Global Research Prefers BeiGene/ SINO BIOPHARM/ HYGEIA HEALTH Given Higher Visibility in CN Pharma & Medical Device Subsectors - AASTOCKS.com
Hutchmed announces progress, hits milestone with lung cancer treatment - ShareCast
Market news - Research the market
Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million - Benzinga
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy - The Manila Times
HUTCHMED Announces NDA Acceptance in China with Priority - GlobeNewswire
Jane Street Group LLC Raises Stock Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
HUTCHMED (China) Limited (NASDAQ:HCM) Shares Purchased by State Street Corp - Defense World
HCMHUTCHMED (China) Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy - The Manila Times
HUTCHMED Announces Breakthrough Therapy Designation in - GlobeNewswire
HUTCHMEDNew sovleplenib clinical data showcased at ASH - Research Tree
Hutchmed endometrial cancer treatment gets conditional approval in China - ShareCast
M&G Plc Has $5.35 Million Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - MarketBeat
How Trump and Harris plan to address housing affordability - Yahoo Finance
Blue Trust Inc. Purchases 3,057 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® - GlobeNewswire
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful - The Bakersfield Californian
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial - Yahoo Finance UK
HUTCHMED (China) Ltd (HCM) (Q2 2024) Earnings Call Highlights: Strong US Sales Propel Growth ... - Yahoo Finance
FDA Approves 16 New Cancer Treatments As Global Cancer Rates Skyrocket - Barchart
Vanguard Personalized Indexing Management LLC Buys 1,168 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
Rhumbline Advisers Boosts Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
Research Analysts Set Expectations for HUTCHMED (China) Limited’s FY2025 Earnings (NASDAQ:HCM) - Defense World
HUTCHMED (LON:HCM) Share Price Crosses Above 200 Day Moving Average of $284.47 - Defense World
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - The Manila Times
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda - Yahoo Finance
CN National Reimbursement Drug List Raises Requirements on Innovative Drugs: Report - AASTOCKS.com
International companies to host live webcasts at Deutsche - GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 - Yahoo Finance
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 - Kirkland Lake Northern News
HUTCHMED (China) Limited (NASDAQ:HCM) Shares Sold by Acadian Asset Management LLC - Defense World
HUTCHMED (LON:HCM) Stock Price Crosses Below 200 Day Moving Average of $283.02 - Defense World
HUTCHMED (LON:HCM) Stock Crosses Below 200 Day Moving Average of $281.77 - Defense World
7 Best-Performing China Stocks for October 2024 - NerdWallet
HUTCHMED Voluntarily Withdraws Supplemental New Drug Application in China for Fruquintinib - AASTOCKS.com
HUTCHMED (LON:HCM) Stock Crosses Below Two Hundred Day Moving Average of $280.85 - Defense World
HUTCHMED (LON:HCM) Share Price Crosses Above 200-Day Moving Average of $277.00 - Defense World
Here is What to Know Beyond Why PDD Holdings Inc. Sponsored ADR (PDD) is a Trending Stock - Yahoo Finance
What Starbucks' new CEO must instantly do to address crisis - Yahoo Finance
Sea Limited (SE) Reportedly Hikes Merchant Fees to Boost Profit - Yahoo Finance
HUTCHMED (China) Limited (NASDAQ:HCM) Shares Sold by Jane Street Group LLC - Defense World
CMBI Raises HUTCHMED (00013.HK) TP to $35.61; Fruquintinib's Overseas Sales Beat - AASTOCKS.com
Hutchmed China Limited Adr (HCM) 財務データ
収益
当期純利益
現金流量
EPS
3.23%
3.94%
大文字化:
|
ボリューム (24 時間):